Allostery in GPCRs: 'MWC' revisited

Trends in Biochemical Sciences

Volumn 36, Issue 12, 2011, Pages 663-672

  Canals, Meritxell ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND;

ALLOSTERISM; DRUG TARGETING; GENOME; MODEL; MONOD WYMAN CHANGEUX MODEL; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ALLOSTERIC SITE; ANIMALS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 82355169577     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2011.08.005     Document Type: Review

References (74)

1. Overington J., et al. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
2. Chien E., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330:1091-1095.
3. Shimamura T., et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011, 475:65-70.
4. Cherezov V., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
5. Jaakola V., et al. The 2.6Å crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
6. Wu B., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
7. Rosenbaum D.M., et al. Structure and function of an irreversible agonist-β2 adrenoceptor complex. Nature 2011, 469:236-240.
8. Neubig R., et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 2003, 55:597-606.
9. Conn P., et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8:41-54.
10. Rasmussen S., et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 10.1038/nature10361.
11. Monod J., et al. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 1965, 12:88-118.
12. Monod J., et al. Allosteric proteins and cellular control systems. J. Mol. Biol. 1963, 6:306-329.
13. Changeux J.P., Edelstein S.J. Allosteric mechanisms of signal transduction. Science 2005, 308:1424-1428.
14. Changeux J.P., Edelstein S.J. Allosteric receptors after 30 years. Neuron 1998, 21:959-980.
15. Whorton M., et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7682-7687.
16. Kuszak A.J., et al. Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. J. Biol. Chem. 2009, 284:26732-26741.
17. Kobilka B.K., et al. Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 1988, 240:1310-1316.
18. Fung J., et al. Ligand-regulated oligomerization of [beta]2-adrenoceptors in a model lipid bilayer. EMBO J. 2009, 28:3315-3328.
19. Milligan G., Bouvier M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J. 2005, 272:2914-2925.
20. Springael J.Y., et al. Allosteric properties of G protein-coupled receptor oligomers. Pharmacol. Ther. 2007, 115:410-418.
21. Han Y., et al. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 2009, 5:688-695.
22. May L., et al. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47:1-51.
23. Smith N.J., Milligan G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 2010, 62:701-725.
24. Rondard P., et al. Functioning of the dimeric GABA(B) receptor extracellular domain revealed by glycan wedge scanning. EMBO J. 2008, 27:1321-1332.
25. Maurel D., et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat. Methods 2008, 5:561-567.
26. Galvez T., et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J. 2001, 20:2152-2159.
27. Goudet C., et al. Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J. Biol. Chem. 2005, 280:24380-24385.
28. Ehlert F.J. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 1985, 28:410-421.
29. Bockaert J., et al. GPCR interacting proteins (GIP). Pharmacol. Ther. 2004, 103:203-221.
30. DeWire S., et al. β-Arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69:483-510.
31. Ritter S., Hall R. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 2009, 10:819-830.
32. Kenakin T. 7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol. Sci. 2009, 30:460-469.
33. Rasmussen S.G.F., et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 2011, 469:175-180.
34. Xu F., et al. Structure of an agonist-bound human A2A adenosine receptor. Science 2011, 332:322-327.
35. Scheerer P., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455:497-502.
36. Gregory K., et al. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol. Chem. 2010, 285:7459-7474.
37. Avlani V.A., et al. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol. Pharmacol. 2010, 78:94-104.
38. Jensen P.C., et al. Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J. Biol. Chem. 2008, 283:23121-23128.
39. Knoflach F., et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13402-13407.
40. Hay D.L., et al. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol. Pharmacol. 2006, 70:1984-1991.
41. Costa T., Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7321-7325.
42. Costa T., Cotecchia S. Historical review: negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol. Sci. 2005, 26:618-624.
43. Stewart G., et al. Inverse agonists. Encyclopedia of Psychopharmacology 2011, 661-669. Springer. I.P. Stolerman (Ed.).
44. Smit M.J., et al. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:53-87.
45. Kenakin T. Allosteric modulators: the new generation of receptor antagonist. Mol. Interv. 2004, 4:222-229.
46. Parra S., Bond R.A. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?. Curr. Opin. Pharmacol. 2007, 7:146-150.
47. Tränkle C., et al. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors. Mol. Pharmacol. 1999, 56:962-965.
48. Keov P., et al. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 2011, 60:24-35.
49. Leach K., et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 2009, 35:855-869.
50. Azzi M., et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11406-11411.
51. Wisler J.W., et al. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16657-16662.
52. Stallaert W., et al. Ligand functional selectivity and quantitative pharmacology at G-protein-coupled receptors. Exp. Opin. Drug Discov. 2011, 6:811-825.
53. Yao X.J., et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9501-9506.
54. Pierce K., Lefkowitz R. Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2001, 2:727-733.
55. Peleg G., et al. Single-molecule spectroscopy of the β(2) adrenergic receptor: observation of conformational substates in a membrane protein. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8469-8474.
56. 2 adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:5997-6002.
57. Gales C., et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat. Struct. Mol. Biol. 2006, 13:778-786.
58. Bokoch M., et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463:108-112.
59. Watson C., et al. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 2005, 67:1268-1282.
60. Suratman S., et al. Impact of species variability and " probe-dependence" on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br. J. Pharmacol. 2011, 162:1659-1670.
61. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 2000, 58:1412-1423.
62. Price M.R. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 2005, 68:1484-1495.
63. Taly A., et al. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov. 2009, 8:733-750.
64. Maillet E.L., et al. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 2007, 21:2124-2134.
65. Marlo J., et al. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol. 2009, 75:577-588.
66. Mathiesen J., et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 2005, 68:393-402.
67. Makita N., et al. An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5443-5448.
68. Coureuil M., et al. Meningococcus hijacks a β2-adrenoceptor/β-arrestin pathway to cross brain microvasculature endothelium. Cell 2010, 143:1149-1160.
69. Andrews G., et al. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol. 2008, 73:855-867.
70. Salchow K., et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharmacol. 2010, 159:1429-1439.
71. Tressel S.L., et al. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol. Biol. 2011, 683:259-275.
72. Sevigny L.M., et al. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8491-8496.
73. Whalen E.J., et al. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
74. Koole C., et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol. Pharmacol. 2010, 78:456-465.